Navigation Links
Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
Date:1/31/2011

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

The technique, called adoptive immunotherapy, works with the body's immune system to fight cancer. Immune cells, called T lymphocytes, are removed, modified, expanded in large numbers, and given back to the patient. In this case, the process entailed genetically engineering T cell lymphocytes to express receptors directed against a specific antigen on the cancer cell.

"We believe that this approach of adoptive immunotherapy is the most effective means for using the body's immune system to combat cancer," said senior study author Steven A. Rosenberg, MD, PhD, chief of the surgery branch at the National Cancer Institute. "This paper represents the first time that adoptive immunotherapy using genetically modified cells has been successfully used to treat a solid cancer other than melanoma because we are targeting an antigen present on many types of cancer."

The treatment resulted in response rates of 45 percent and 67 percent in malignant melanoma and synovial cell sarcoma patients, respectively.

In earlier trials, Rosenberg and colleagues used adoptive immunotherapy on treatment-resistant patients with metastatic melanoma who had extensive prior therapy. Of 93 patients studied, they found that more than half had measurable responses, including 20 with complete disappearance of all melanoma metastases.

In the current study, 17 patients with treatment-resistant metastatic melanoma or metastatic synovial cell sarcoma received therapy with their own immune T cells. The cells were genetically engineered to express a T cell receptor that recognized the NY-ESO-1 cancer-testes antigen on cancer cells. NY-ESO-1 is expressed in one quarter to one third of common epithelial cancers such as those of the breast, kidney, esophagus and other cancer types, and in about 80 percent of synovial cell sarcoma.

Four of six patients (67 percent) with synovial cell sarcoma and five of 11 (45 percent) melanoma patients had measurable tumor regression. Two of the 11 melanoma patients had complete regression lasting for more than one year. The treatments had minimal toxicity.

"The effectiveness of this treatment in patients with synovial cell sarcoma may mean that this new approach can be used for patients with other cancers as well," Rosenberg said, "And potentially lead to new types of immunotherapy. "

Rosenberg's group recently reported the first example of using adoptive immunotherapy to treat a patient with non-Hodgkin's lymphoma, and continues to explore different ways to genetically modify a patient's immune system to treat cancer. They have also recently published results showing that immune cells could be genetically modified to target and destroy the blood vessels supplying nutrients to tumors in experimental models.


'/>"/>

Contact: Kelly Powell
kelly.powell@asco.org
571-483-1365
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: